CDK4 and hepatocellular carcinoma: In another in vitro study, Bollard et al. (2017) mentioned that when used alone or in combination with sorafenib, pablociclib, a CDK4 and CDK6 inhibitor, suppressed proliferation in Hep G2 and other human HCC cell lines depending on dose and time.